51. Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
- Author
-
Vivek N. Iyer, Yahya Almodallal, Hasan Ahmad Hasan Albitar, and Rick A. Nishimura
- Subjects
Aortic valve ,medicine.medical_specialty ,Bevacizumab ,Cardiac index ,Case Report ,HHT, hereditary hemorrhagic telangiectasia ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Mitral valve ,medicine ,Cardiac structure ,In patient ,030212 general & internal medicine ,CI, cardiac index ,Telangiectasia ,HOCF, high-output cardiac failure ,LAAC, left atrial appendage closure ,Gastrointestinal tract ,lcsh:R5-920 ,business.industry ,GI, gastrointestinal tract ,Surgery ,medicine.anatomical_structure ,TTE, transthoracic echocardiography ,medicine.symptom ,business ,lcsh:Medicine (General) ,IV, intravenous ,medicine.drug - Abstract
Bevacizumab is now an emerging treatment option for severe hereditary hemorrhagic telangiectasia–related bleeding including epistaxis and gastrointestinal tract bleeding. The impact of long-term intravenous bevacizumab therapy on cardiac structure and function is unknown. We describe 3 patients receiving intravenous bevacizumab therapy for severe hereditary hemorrhagic telangiectasia–related bleeding who were found to have abnormal mobile masses on the mitral valve (n=2) and aortic valve (n=1). The clinical impact of these findings is unknown and requires further study.
- Published
- 2020